Lyka Labs share news, announcements and annual reports
NSE: LYKALABSBSE: 500259Pharmaceuticals & BiotechnologySmall Cap
Lyka Labs Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 1986 on BSE, Feb 1995 on NSE
Last close ₹76.60up ₹0.35 (0.46%)BSE ₹77.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹76.25.
30 Oct: open ₹77.77, high ₹77.77, low ₹76.60
52-week range of traded prices to 30 Oct 2026
₹44.10Low, 30 Mar 2026₹98.25High, 31 Oct 2025
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Next results date: the board meets on 30 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹277 Cr2,310th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.00
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −9.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −8.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.53
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 6,475
Lyka Labs orders, deals and press releases
65 filed, newest first. Page 2 of 2.
May 2017
Jun 2016
4 Jun · Business
Revision in appointed date of merger
Apr 2016
11 Apr · Business
Launch of New Marketing Divisions
Mar 2016
5 Mar · Business
Board Meeting on Mar 11, 2016
Nov 2015
Oct 2015
Feb 2015
Dec 2014
18 Dec · Business
Board Meeting Adjourned to Dec 24, 2014
Sep 2014
29 Sep · Business
Sale of Manufacturing Facilities at Tarapur
Dec 2011
30 Dec · Business
Updates - Agreement for Transfer of Know How/ Technology
Nov 2011
25 Nov · Business
Technical Assistance Agreement4 Nov · Business
Patent Award
Sep 2010
30 Sep · Business
Silver Patent Award
Nov 2007
8 Nov · Business
At the meeting of the Board of Directors of the Company at its Meeting held on November 7, 2007, it was decided that the Company will issue upto 36,50,000 Equity Shares to Foreign investor/Business Associates/ Body Corporates and Other Domestic Investors at Rs.55/- per share on the terms and conditions as per the SEBI Guidelines on preferential issue dated August 4, 1994. The Board has also decided to issue 22,00,000 Equity Warrants to the Promoters and Business Associates at an exercise price of Rs.55/- per warrant on the terms and conditions as per the SEBI Guidelines on Preferential issue. The Chairman has been authorized to take necessary steps and to call an Extra Ordinary General Meeting to consider passing of the Special resolution under Section 81(1A) of the companies Act, 1956."